Application of glycyrrhizic acid on treating dilated cardiomyopathy cardiac remodeling and cardiac dysfunction

A technology of dilated cardiomyopathy and glycyrrhizic acid, applied in the field of medicine, can solve problems such as cardiac remodeling

Inactive Publication Date: 2011-11-23
INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A large number of studies have shown that the onset of dilated heart disease is related to inflammation and autoimmune abnormalities caused by viral infection, but epidemiological research data show that only 60% of patients with dilated heart disease have a history of viral infection [4] Therefore, viral infection and the autoimmune response triggered by it have not been generally accepted as the etiology of directly causing dilated heart disease, and people have not been able to explain what pathological mechanism mediates the development of cardiac tissue in the case of some non-infectious factors involved. The infiltration of inflammatory cells and the expression of inflammatory factors in the heart eventually lead to the appearance of cardiac remodeling

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of glycyrrhizic acid on treating dilated cardiomyopathy cardiac remodeling and cardiac dysfunction
  • Application of glycyrrhizic acid on treating dilated cardiomyopathy cardiac remodeling and cardiac dysfunction
  • Application of glycyrrhizic acid on treating dilated cardiomyopathy cardiac remodeling and cardiac dysfunction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0030] Materials and Methods

[0031] 1. Reagents and instruments

[0032] 1. Main reagents and medicines

[0033] Doxorubicin (Doxorubicin, DOX): Shenzhen Wanle Pharmaceutical Co., Ltd., batch number: 20081025;

[0034] Glycyrrhizin (Glycyrrhizin): Merck Company, Catalog NO: 356780-5GM;

[0035] 2. Experimental animals

[0036] SPF grade ICR mice (male, 10 weeks old, weighing 26-30 g) were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., animal certificate number SCXK (Beijing) 2008-0001. They were raised in the Experimental Animal Center of the Institute of Materia Medica, Chinese Academy of Medical Sciences, with constant temperature and humidity, and free diet.

[0037] 2. Experimental method

[0038] 1. Preparation of doxorubicin-induced cardiomyopathy model mice

[0039] The ICR mice were sterilized with 75% alcohol in the abdomen, and a single intraperitoneal injection of doxorubicin (10 mg / kg) was used to establish the model. After ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of glycyrrhizic acid on preventing, curing and alleviating dilated cardiomyopathy, comprising the steps of inhibiting cardiac abnormal remodeling, improving cardiac dysfunction and improving heart tissue fibrosis of dilated cardiomyopathy patients, wherein the step of inhibiting cardiac abnormal remodeling comprises the steps of inhibiting the ventricular dilatation of dilated cardiomyopathy patients, especially the abnormal dilatation of the ventriculus sinister or bilateral sinister; and the step of improving cardiac dysfunction means the operation of improving systolic and diastolic function obstacles of the dilated cardiomyopathy patients.

Description

technical field [0001] The invention discloses the application of glycyrrhizic acid in the preparation of medicines for preventing, treating and alleviating dilated cardiomyopathy; it belongs to the technical field of medicine. Background technique [0002] Dilated cardiomyopathy seriously endangers human life and health. Primary cardiomyopathy is a kind of cardiomyopathy with unknown cause and mainly characterized by cardiac dysfunction [1] . Dilated cardiomyopathy (dilated heart disease) accounts for about 70-80% of primary cardiomyopathy and is the most important type of primary cardiomyopathy. Its main clinical manifestations are abnormal enlargement of left ventricle or double ventricle, decreased ventricular systolic and diastolic function, severe heart failure and arrhythmia. There is no effective treatment for this disease so far, and various treatment methods can only improve the symptoms of heart failure and complications. Most patients die due to progressive ag...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P9/00
Inventor 胡卓伟张晓伟蔡文锋马永刚闫慧敏
Owner INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap